SEARCH

SEARCH BY CITATION

References

  • 1
    Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 831.
  • 2
    Wingo PA, Tong T, Bolden S: Cancer statistics, 1995. CA Cancer J Clin 1995; 45: 830.
  • 3
    Fiorca JV, Roberts WS: Screening for ovarian cancer. Cancer Control 1996; 3: 120129.
  • 4
    Kerlikowske K, Brown JS, Grady DG: Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol 1992; 80: 700707.
  • 5
    Greggi S, Genuardi M, Benedetti-Panici P, et al: Analysis of 138 consecutive ovarian cancer patients: Incidence and characteristics of familial cases. Gynecol Oncol 1990; 39: 300304.
  • 6
    Houlston RS, Collins A, Slack J, et al: Genetic epidemiology of ovarian cancer: Segregation analysis. Ann Hum Genet 1991; 55: 291299.
  • 7
    Piver MS, Baker TR, Jishi MF, et al: Familial ovarian cancer: A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981–1991. Cancer 1993; 71 (Suppl 2): 582588.
  • 8
    Lynch HT, Watson P, Bewtra C, et al: Hereditary ovarian cancer: Heterogeneity in age at diagnosis. Cancer 1991; 67: 14601466.
  • 9
    Bewtra C, Watson P, Conway T, et al: Hereditary ovarian cancer: A clinicopathological study. Int J Gynecol Pathol 1992; 11: 180187.
  • 10
    Schildkraut JM, Risch N, Thompson WD: Evaluating genetic association among ovarian, breast, and endometrial cancer: Evidence for a breast/ovarian cancer relationship. Am J Hum Genet 1989; 45: 521529.
  • 11
    Lynch HT, Conway T, Lynch J: Hereditary ovarian cancer: Pedigree studies, part II. Cancer Genet Cytogenet 1991; 53: 161183.
  • 12
    Watson P, Lynch HT: Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993; 71: 677685.
  • 13
    Lynch HT, Lemon SJ, Karr B, et al: Etiology, natural history, management, and molecular genetics of herediary nonpolyposis colorectal cancer (Lynch Syndromes): Genetic counseling implications. Cancer Epidemiol Biomarkers Prev 1997; 6: 987991.
  • 14
    Narod SA, Madlensky L, Bradley L, et al: Hereditary and familial ovarian cancer in southern Ontario. Cancer 1994; 74: 23412346.
  • 15
    Steichen-Gersdorf E, Gallion HH, Ford D, et al: Familial site-specific ovarian cancer is linked to BRCA1 on 17q12–21. Am J Hum Genet 1994; 55: 870875.
  • 16
    Easton DF, Bishop DT, Ford D, et al: Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993; 52: 678701.
  • 17
    Narod SA, Ford D, Devilee P, et al: An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 1995; 56: 254264.
  • 18
    Wooster R, Neuhausen S, Mangion J, et al: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. Science 1994: 20882090.
  • 19
    Narod S, Ford D, Devilee P, et al: Genetic heterogeneity of breast-ovarian cancer revisited. Am J Hum Genet 1995; 57: 957958. Letter.
  • 20
    Boyd J: Molecular genetics of hereditary ovarian cancer. Oncology 1998; 12: 399406.
  • 21
    Young RC, Perez CA, Hoskins WJ: Cancer of the ovary, in DevitaVTJr, HellmanS, RosenbergSA (eds): Cancer: Principles & Practice of Oncology, ed 4. Philadelphia, JP Lippincott Co, 1993, pp 12261263.
  • 22
    Ozols RF: Ovarian cancer, part II: Treatment. Curr Probl Cancer 1992; 16: 61126.
  • 23
    The WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Epithelial ovarian cancer and combined oral contraceptives. Int J Epidemiol 1989; 18: 538545.
  • 24
    Hankinson SE, Hunter DJ, Colditz GA, et al: Tubal ligation, hysterectomy, and risk of ovarian cancer: A prospective study. JAMA 1993; 270: 28132818.
  • 25
    Tobacman JK, Green MH, Tucker MA, et al: Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 1982; 2: 795797.
  • 26
    Piver MS, Jishi MF, Tsukada Y, et al: Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993; 71: 27512755.
  • 27
    Struewing JP, Watson P, Easton DF, et al: Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst 1995; 17: 3335.
  • 28
    McFarlane C, Sturgis MD, Fetterman FC: Results of an experience in the control of cancer of the female pelvic organs: A report of a 15-year research. Am J Obstet Gynecol 1956; 69: 294301.
  • 29
    Squatrito RC, Buller RE: Use of serum CA-125 for monitoring and prognosticating outcome in patients with epithelial ovarian cancer. The Female Patient 1994; 19: 14.
  • 30
    Gadducci A, Ferdeghini M, Prontera C, et al: The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: Relevance for differential diagnosis. Gynecol Oncol 1992; 44: 147154.
  • 31
    Berek J, Bast RC Jr: Ovarian cancer screening: The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer 1995; 76 (Suppl 10): 20922096.
  • 32
    Zurawski V, Sjovall K, Schoenfeld D, et al: Prospective evaluation of serum CA-125 levels in a normal population, Phase I: The specificities of single and serial determinations in testing for ovarian cancer. Gynecol Oncol 1990; 36: 299305.
  • 33
    DePriest PD, van Nagel Jr, Gallion HH, et al: Ovarian cancer screening in asymptomatic post-menopausal women. Gynecol Oncol 1993; 51: 205209.
  • 34
    Weiner Z, Thaler I, Beck D, et al: Differentiating malignant from benign ovarian tumors with transvaginal color flow imaging. Obstet Gynecol 1992; 79: 159162.
  • 35
    Bourne TH, Campbell S, Reynolds KM, et al: Screening for early familial ovarian cancer with transvaginal ultrasonography and colour flow imaging. BMJ 1993; 306: 10251029.
  • 36
    Caruso A, Caforio L, Testa A, et al: Transvaginal color Doppler ultrasonography in the presurgical characterization of adnexal masses. Gynecol Oncol 1996; 63: 184191.
  • 37
    Karlan BY, Platt LD: The current status of ultrasound and color Doppler imaging in screening for ovarian cancer. Gynecol Oncol 1994; 55: S28S33.
  • 38
    NIH Consensus Development Conference Panel. Ovarian Cancer: Screening, Treatment, and Follow-up. Washington DC, National Institutes of Health, April 5–7, 1994. NIH Consensus Statement 12.
  • 39
    Kramer BS, Gohagan J, Propok PC, et al: A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 1993; 71 (Suppl 2): 589593.
  • 40
    Menko FH, Wijnen JT, Khan PM, et al: Genetic counseling in hereditary nonpolyposis colorectal cancer. Oncology 1996; 10: 7176.
  • 41
    Burke W, Petersen G, Lynch P, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. JAMA 1997; 277: 915919.
  • 42
    Burke W, Daly M, Garber J, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. JAMA 1997; 277: 9971003.
  • 43
    Flam F, Einhorn N, Sjovall K: Symptomatology of ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1988; 27: 5357.
  • 44
    Finn CB, Luesley DM, Buxton EJ, et al: Is stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review. Br J Obstet Gynecol 1992; 99: 5458.
  • 45
    Goldstein SR: Postmenopausal adnexal cysts: How clinical management has evolved. Am J Obstet Gynecol 1996; 175: 14981501.
  • 46
    Childers JM, Nasseri A, Surwit EA: Laparoscopic management of suspicious adnexal masses. Am J Obstet Gynecol 1996; 175: 14511457.
  • 47
    Hoskins WJ: Epithelial ovarian carcinoma: Principles of primary surgery. Gynecol Oncol 1994; 55: S91S96.
  • 48
    Hoskins WJ, McGuire WP, Brady MF, et al: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 170: 974979.
  • 49
    Piver MS, Lele SB, Marchetti DL, et al: The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol 1988; 6: 983989.
  • 50
    Eisenkop SM, Nalick RH, Teng NN: Modified posterior exenteration for ovarian cancer. Obstet Gynecol 1991; 78: 879885.
  • 51
    Barnes W, Johnson J, Waggoner S, et al: Reverse hysterocolposigmoidectomy (RHCS) for resection of panpelvic tumors. Gynecol Oncol 1991; 42: 151155.
  • 52
    Burghardt E, Pickel H, Lahousen M, et al: Pelvic lymphadenectomy in operative treatment of ovarian cancer. Am J Gynecol 1986; 155: 315319.
  • 53
    Kigawa J, Minagawa Y, Ishihara H, et al: Evaluation of cytoreductive surgery with lymphadenectomy including para-aortic nodes for advanced ovarian cancer. Eur J Surg Oncol 1993; 19: 273278.
  • 54
    Spirtos NM, Gross GM, Freddo JL, et al: Cytoreductive surgery in advanced epithelial cancer of the ovary: The impact of aortic and pelvic lymphadenectomy. Gynecol Oncol 1995; 56: 345352.
  • 55
    Lippman SM, Alberts DS, Slymen DJ, et al: Second-look laparotomy in epithelial ovarian carcinoma: Prognostic factors associated with survival duration. Cancer 1988; 61: 25712577.
  • 56
    Luesley D, Lawton F, Blackledge G, et al: Failure of second-look laparotomy to influence survival in epithelial ovarian cancer. Lancet 1988; 2: 599603.
  • 57
    Hoskins WJ, Rubin SC, Dulaney E, et al: Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian cancer. Gynecol Oncol 1989; 34: 365371.
  • 58
    Podratz KC, Schray MF, Wieand HS, et al: Evaluation of treatment and survival after positive second-look laparotomy. Gynecol Oncol 1988; 31: 924.
  • 59
    Michel G, Zarca D, Castaigne D, et al: Secondary cytoreductive surgery in ovarian cancer. Eur J Surg Oncol 1989; 15: 201204.
  • 60
    Janicke F, Holscher M, Kuhn W, et al: Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 1992; 70: 21292136.
  • 61
    van der Burg, ME, van Lent M, Buyse M, et al: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995; 332: 629634.
  • 62
    Ozols RF, Rubin SC, Dembo AJ, et al: Epithelial ovarian cancer, in HoskinsWJ, PerezCA, YoungRC, (eds): Principles and Practice of Gynecologic Oncology, Philadelphia, JB Lippincott, 1992, pp 731781.
  • 63
    Young RC, Walton LA, Ellenberg SS, et al: Adjuvant therapy in stage I and stage II epithelial ovarian cancer: Results of two prospective randomized trials. N Engl J Med 1990; 322: 10211027.
  • 64
    Bolis G, Colombo N, Pecorelli S, et al: Adjuvant treatment for early epithelial ovarian cancer: Results of two randomized clinical trials comparing cisplatin to no further treatment or chromic phosphate. Ann Oncol 1995; 6: 887893.
  • 65
    Vergote IB, Vertoge-DeVos LN, Abeler VM, et al: Randomized trial comparing cisplatin with radioactive phosphorous or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 1992; 69: 741749.
  • 66
    Ozols R, Rubin S, Thomas G, et al: Epithelial ovarian cancer, in HoskinsWJ, PerezCA, YoungRC (eds) Principles and Practice of Gynecologic Oncology, ed 2. Philadephia, Lippincott-Raven Publishers, 1997, p 947.
  • 67
    Bolis G, Colombo N, Pecorelli S, et al: Adjuvant treatment for early epithelial ovarian cancer: Results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol 1995; 6: 887893.
  • 68
    McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 16.
  • 69
    Young RC, Chabner BA, Hubbard SP, et al: Advanced ovarian adenocarcinoma: A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med 1978; 299: 12611266.
  • 70
    Omura GA, Blessing JA, Ehrlich CE, et al: A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. Cancer 1986; 57: 17251730.
  • 71
    Omura GA, Siller BS: Primary chemotherapy of epithelial ovarian carcinoma. Semin Surg Oncol 1994; 10: 283287.
  • 72
    Gruppo Interregionale Collaborativo in Ginecologia Oncologica: Randomized comparison of cisplatin with cyclosphosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet 1987; 2: 353359.
  • 73
    Omura GA, Bundy BN, Berek JS, et al: Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 1989; 7: 457465.
  • 74
    Bertelsen K, Jakobsen A, Andersen J, et al: A randomized study of cyclophosphamide and cisplatinum with or without doxorubicin in advanced ovarian carcinoma. Gynecol Oncol 1987; 28: 161169.
  • 75
    Conte PF, Bruzzone M, Chiara S, et al: A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophophosphamide in advanced ovarian cancer. J Clin Oncol 1986; 4: 965971.
  • 76
    Ovarian Cancer Meta-Analysis Project: Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis. J Clin Oncol 1991; 9: 16681674.
  • 77
    McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273279.
  • 78
    Omura GA, Morrow CP, Blessing JA, et al: A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer 1983; 51: 783789.
  • 79
    Advanced Ovarian Cancer Trialists Group: Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials. BMJ 1991; 303: 884893.
  • 80
    Thigpen T, Vance R, Puneky L, et al: Chemotherapy in advanced ovarian carcinoma: Current standards of care based on randomized trials. Gynecol Oncol 1994; 55: S97S107.
  • 81
    Bertelsen K, Jakobsen A, Stroyer J, et al: A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: A Danish Ovarian Study Group trial. Gynecol Oncol 1993; 49: 3036.
  • 82
    Hakes TB, Chalas E, Hoskins WJ, et al: Randomized prospective trial of 5 versus 10 cycles of cyclophophamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992; 45: 284289.
  • 83
    Ozols RF: Update of the NCCN ovarian cancer practice guidelines. Oncology 1997; 11: 95105.
  • 84
    Thomas GM: Radiotherapy in early ovarian cancer. Gynecol Oncol 1994; 55: S73S79.
  • 85
    Morrow CP, Curtin JP, Townsend DE: Tumors of the ovary: Neoplasms derived from coelomic epithelium, in MorrowCP, CurtinJP, TownsendDE (eds): Synopsis of Gynecologic Oncology, ed 4. New York, Churchill Livingstone, 1993, p 265.
  • 86
    Jacobs I, Bast RC Jr: The CA 125 tumor-associated antigen: A review of the literature. Hum Reprod 1989; 4: 112.
  • 87
    Berek JS, Knapp RC, Malkasian GD, et al: CA 125 serum levels correlated with second-look operations among ovarian cancer patients. Obstet Gynecol 1986; 69: 685689.
  • 88
    Ozols RF, Ostchega M, Myers CE, et al: Highdose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 1985; 3: 12461250.
  • 89
    Gershenson DM, Kavanaugh JJ, Copeland LJ, et al: Retreatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy. Obstet Gynecol 1989; 73: 798802.
  • 90
    Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389393.
  • 91
    Ozols RF, Ostchega Y, Curt G, et al: High-dose carboplatin in refractory ovarian cancer patients. J Clin Oncol 1987; 5: 197201.
  • 92
    Kavanaugh J, Tresukosol D, Edwards C, et al: Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 1995; 13: 15841588.
  • 93
    Ten Bokkel Huinink W, Gore M, Carmichael J, et al: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 21832193.
  • 94
    Lund B, Hansen OP, Theilade K, et al: Phase II study of gemcitabine (2′, 2′-diflourodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86: 15301533
  • 95
    Bajetta E, Di Leo A, Bignanzoli L, et al: Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: Activity in platinum resistant disease. J Clin Oncol 1996; 14: 25462551.
  • 96
    Muggia FM, Hainsworth JP, Jeffers S, et al: Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987993.
  • 97
    Rose PG, Blessing JA, Mayer AR, et al: Prolonged oral etoposide as second line therapy for platinum resistant (PLATR) and platinum sensitive (PLATS) ovarian carcinoma: A Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 1996; 15: 282. Abstract.
  • 98
    Schray MF, Martinez A, Howes AE, et al: Advanced epithelial ovarian cancer: Salvage whole abdominal irradiation for patients with recurrent or persistent disease after combination chemotherapy. J Clin Oncol 1988; 6: 14331439.
  • 99
    Weiss G, Green S, Alberts DS, et al: Second-line treatment of advanced measurable ovarian cancer with iproplatin: A Southwest Oncology Group study. Eur J Cancer 1991; 27: 135138.
  • 100
    Willemse PHA, Gietema AJ, Mulder NH, et al: Zeniplatin in patients with advanced ovarian cancer: A Phase II study with a third generation platinum complex. Eur J Cancer 1993; 29: 359362.
  • 101
    Markman M, DeMarco LC, Birkhofer M, et al: Phase II trial of zeniplatin (CL 286558) a new platinum compound in patients with advanced ovarian cancer previously treated with organoplatinum based therapy. J Cancer Res Clin Oncol 1993; 119: 234236.
  • 102
    Gietema JA, Veldhuis GJ, Guchelaar HJ, et al: Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. Br J Cancer 1995; 71: 13021307.
  • 103
    Hoskins PJ, Swenerton KD: Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994; 12: 6063.
  • 104
    Seymour MT, Mansi JL, Gallagher CJ, et al: Protracted oral etoposide in epithelial ovarian cancer: A phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 1994; 69: 191195.
  • 105
    de Wit R, van der Burg M, van den Gaast A, et al: Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. Ann Oncol 1994; 5: 656657.
  • 106
    Trimble EL, Adams JD, Vena D, et al: Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1000 patients registered to National Cancer Institute treatment referral center 9103. J Clin Oncol 1993; 11: 24052410.
  • 107
    Thigpen JT, Blessing JA, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 1994; 12: 17481753.
  • 108
    Bruzzone M, Catsafados E, Miglietta L: Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients. Oncology 1996; 53: 349536.
  • 109
    Nardi M, Aloe A, DeMarco S, et al: Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: A phase II study. Am J Clin Oncol 1997; 20: 230232.
  • 110
    Piccart MJ, Gore M, Ten Bokkel Huinink W, et al: Docetaxel: An active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995; 87: 676681.
  • 111
    Armstrong D, Rowinsky E, Donehower R, et al: A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer. Proc Am Soc Clin Oncol 1995; 14: 275. Abstract.
  • 112
    Creemers GJ, Bolis G, Gore M, et al: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 1996; 14: 30563061.
  • 113
    Kudelka AP, Treskosol D, Edwards CL, et al: Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996; 14: 15521557.
  • 114
    Swisher EM, Mutch DG, Rader JS, et al: Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 1997; 66: 480486.
  • 115
    Manetta A, Blessing JA, Look KY: A phase II study of Fazarabine in patients with advanced ovarian cancer: A Gynecologic Oncology Group study. Am J Clin Oncol 1995; 8: 156157.
  • 116
    Vermorken JB, Kobierska A, van der Burg ME, et al: High-dose epirubicin in platinum-pre-treated patients with ovarian carcinoma: The EORTC-GCCG experience. Eur J Gynaecol/Oncol 1995; 16: 433438.
  • 117
    Vergote I, Himmelmann A, Frankendal B, et al: Hexamethylmelamine as a second-line therapy in platinum resistant ovarian cancer. Gynecol Oncol 1992; 47: 282286.
  • 118
    Markman M, Hakes T, Reichman B, et al: Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol 1992; 10: 243248.
  • 119
    Judson I, Calvert AH, Gore ME, et al: Phase II trial of trimelamol in refractory ovarian cancer. Br J Cancer 1991; 63: 311313.
  • 120
    Broun ER, Iseminger KA, Bookman M: A phase II trial of edatrexate in previously treated ovarian cancer: A Gynecologic Oncology Group study. Am J Clin Oncol 1995; 18: 164166.
  • 121
    Van Oosterom AT, Ten Bokkel Huinink W, van der Burg ME, et al: Phase II clinical trial of doxifluridine in patients with advanced ovarian cancer. Eur J Cancer 1991; 27: 747749.
  • 122
    Look KY, Blessing JA, Adelson MD, et al: A phase II trial of merbarone (NSC 336628) in the treatment of recurrent epithelial ovarian carcinoma: A Gynecologic Group study. Am J Clin Oncol 1996; 19: 79.
  • 123
    Albain KS, Liu PY, Hantel A, et al: A phase II trial of piroxantrone in advanced ovarian carcinoma after failure of platinum-based chemotherapy: Southwest Oncology Group Study 8904. Gynecol Oncol 1995; 57: 407411.
  • 124
    Malfetano JH, Blessing JA, Jacobs A: A phase II trial of Didemnin B (NSC #335319) in patients with previously treated epithelial ovarian cancer: A Gynecologic Oncology Group study. Am J Clin Oncol 1993; 16: 479.